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involvement of several areas of the central nervous system (CNS), including hippocampus.
Although neurons have been the target of most studies reported in the literature, recently,
considerable attention has been centered upon the functionality and plasticity of glial
cells, particularly astrocytes. These cells participate in normal brain development and also
in neuropathological processes. The present work investigated hippocampi from 15 (P15)
and 120 (P120) days old male rats prenatally exposed to valproic acid (VPA) as an animal
model of autism. Herein, we analyzed astrocytic parameters such as glutamate transporters
and glutamate uptake, glutamine synthetase (GS) activity and glutathione (GSH) content. In
the VPA group glutamate uptake was unchanged at P15 and increased 160% at P120; the
protein expression of GLAST did not change neither in P15 nor in P120, while GLT1 decreased
40% at P15 and increased 92% at P120; GS activity increased 43% at P15 and decreased 28% at
P120; GSH content was unaltered at P15 and had a 27% increase at P120. These data highlight
that the astrocytic clearance and destination of glutamate in the synaptic cleft might be
altered in autism, pointing out important aspects to be considered from both pathophysiologic
and pharmacological approaches in ASD.
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The term Autism Spectrum Disorder (ASD) refers to a group of
conditions characterized by deficits in social interaction, lan-
guage and communication impairments and repetitive and
stereotyped behaviors. As stated in the Diagnostic and Statis-
tical Manual of Mental Disorders-IV-Text Revision (DSM-IV-TR),
ASD comprises Autistic Disorder (also called ‘‘classic’’ autism),
Pervasive Development Disorder Not Otherwise Specified (PDD-
NOS), and Asperger’s Disorder (Gadia et al., 2004). According to
the DSM-V draft, the autism spectrum described in DSM-IV will
be reorganized as a single category of ASD.
Although different theories have emerged trying to solve the
autism puzzle and research has evolved, its etiology remains
unknown and we still lack an objective diagnostic criteria and
treatment options. Genetic factors such as mutations, deletions
and copy number variants are implicated in causation of autism
(Abrahams and Geschwind, 2008; Grigorenko, 2009). However,
epidemiological studies have evidenced that adverse environ-
mental conditions such as maternal exposure to infections,
ethanol, thalidomide and Valproic Acid (VPA) increase the risk
of autistic offspring (Arndt et al., 2005; Dufour-Rainfray et al.,
2011). This might be one of the explanations to the increasing
autism prevalence mainly when combined with changes in
diagnostic practice. In fact, the number of children known to
have autism has increased dramatically since the 1980s. The
Centers for Disease Control and Prevention (CDC) estimate the
prevalence of autism in the United States to be 1 in 88 children,
which generates a national cost of $137 billion per year.
After clinical and animal studies, many encephalic struc-
tures have been implicated in autism pathology and these
include the cerebellum (Amaral et al., 2008; Courchesne and
Pierce, 2005), frontal cortex (Courchesne and Pierce, 2005),
amygdala (Schultz, 2005), cingulate cortex (Oblak et al.,
2009,2011) and the hippocampus (Courchesne and Pierce,
2005; Raymond et al., 1996). Some alterations documented
in autism are however, age-dependent. Brain size, for example,
which is greater in autistic child when compared to control
individuals but reaches normal values when analyzed in
adolescents or adults, is one of the most consistent alterations
(Amaral et al., 2008) and seems to be related to another
discovery showing cortical thinning with age in autism
(Wallace et al., 2010). Gray matter and amygdala volumes have
also been studied in autistic subjects and different results were
found depending on age (Greimel et al., 2012; Schumann et al.,
2004). In a recent publication, age-dependent patterns of gene
expression were found in the autistic prefrontal cortex. Some
authors have shown that in autism, young prefrontal cortex
shows impaired developmental pathways while the adult one
displays arrested growth and degeneration (Chow et al., 2012).
There are also evidences showing that specific neurotrans-
mitter systems may be altered; such as serotonin, GABA
(Oblak et al., 2009; Oblak et al., 2010), glutamate (Choudhury
et al., 2011) and others (Lam et al., 2006).
Although most studies focus on neuronal parameters, glial
cells have been gaining more attention in the last years. It is
known that astrocytes, the third component of the synapse
(Araque et al., 1999), are able to process synaptic informa-
tion displaying bidirectional communication with neurons(Araque et al., 2001; Perea et al., 2009). These cells have also
emerged as sophisticated elements participating in a variety
of processes required to normal brain development and,
consequently, might be involved in different brain disorders.
Some studies have found astroglial activation in brains from
patients with autism (Anderson et al., 2008; Vargas et al.,
2005) with increased GFAP expression (Laurence and Fatemi,
2005), alterations in aquaporins and conexins (Fatemi et al.,
2008) and mutant glial adhesion molecules (Lopez-Hernandez
et al., 2011).
When looking at astrocytes, it is important to take the
glutamatergic system into account once those cells are essential
to the homeostasis of this neurotransmitter. After the uptake of
glutamate through excitatory amino acid transporters 1 (GLAST)
and 2 (GLT1), astrocytes are able to convert this neurotransmitter
into glutamine via glutamine synthetase (GS) (Bak et al., 2006;
Danbolt, 2001). Glutamine, in turn, is taken up by glutamatergic
neurons and used for the resynthesis of glutamate. Glutamate
can also be used as a substrate per se for glutathione (GSH)
synthesis (Dringen et al., 1999). Glutamate is known to be
involved in the control of neuronal migration, differentiation,
neurite outgrowth, synaptogenesis and neuron survival in the
developing brain (Choudhury et al., 2011). In addition, some
authors hypothesize that many core features of autism are
caused by abnormalities in glutamatergic system (Blaylock and
Strunecka, 2009; Choudhury et al., 2011; Gadow et al., 2010;
Gottfried and Riesgo, 2011; Purcell et al., 2001). Thus, by means of
the VPA-induced animal model of autism (Bambini-Junior et al.,
2011) we characterized important astrocytic parameters named
glutamate uptake, GALST and GLT1 immunocontent, GS activity
and the amount of GSH, in the hippocampus from young and
adult male rats prenatally exposed to VPA.2. Results
2.1. Glutamate uptake
As the excitotoxicity of the neurotransmitter glutamate has
been shown to be connected with many acute and chronic
diseases of the CNS, particularly in the hippocampus, and
that the high affinity sodium-dependent glutamate transpor-
ters play a key role in maintaining adequate levels of extra-
cellular glutamate, we decided to evaluate the in vitro profile
of hippocampal glutamate uptake at P15 and P120 rats from
both VPA and control groups (Fig. 1). Values are expressed as
nmol/mg protein/min. The glutamate uptake at P15 was
unchanged between VPA (1.8370.22) and control (1.8570.20)
groups. However, at P120, there was a significantly increase in
glutamate uptake in VPA group (0.9970.07), compared to the
control (0.3870.05), Po0.01. Interestingly, among control
groups, glutamate uptake was 80% lower in P120 than in P15.2.2. GLAST and GLT1 immunocontent
Once glutamate uptake depends mainly upon astrocytic
glutamate transporters, named GLAST and GLT1, we decided
to evaluate their immunocontent in order to understand the
differences found in glutamate uptake.
Fig. 1 – The effect of prenatal exposure to VPA on hippocampal
glutamate uptake. Homogenized tissue samples were
incubated as described in experimental procedure section.
Each sample was measured in triplicate and data analysis
was performed by Student’s t test. Data represent the
mean7SE values. (A) P15 (n¼5) and (B) P120 (n¼4) days old
rats. Statistically significant difference from control values
is indicated by Po0.01.
Fig. 2 – The effect of prenatal exposure to VPA on hippocampal
GLAST immunocontent. Homogenized tissue samples were
incubated as described in experimental procedure section.
Each sample was measured in duplicate and data analysis
was performed by Student’s t test. Data represent the
mean7SE values. (A) P15 (n¼4) and (B) P120 (n¼4) days old
rats. Statistically significant difference from control values
is indicated by Po0.05 and #Po0.01.
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when VPA group was compared to the control group in both
P15 (1.4270.06 and 1.6770.12, respectively) and P120
(1.1470.15 and 1.0270.12, respectively) rats. However, GLT1
immunocontent decreased 40% in VPA-P15 animals
(1.4870.22) when compared to the control group (0.887
0.06), Po0.05 (Fig. 3A). Interestingly, GLT1-P120 (Fig. 3B)
increased 92% in VPA (0.7070.07) group when compared to
the control group (1.3570.19), Po0.01.
2.3. Glutamine synthetase activity
Aiming to understand a possible destiny to the intracellular
glutamate, particularly at P120 which had a higher glutamate
uptake, we investigated hippocampal GS activity (expressed
as mmol/h/mg protein). At P15 (Fig. 4A), GS activity increased
43% in VPA group (3.1370.28) when compared to control rats
(2.1970.1), Po0.05. However, for our surprise, at P120 (Fig. 4B)
the activity of GS decreased 28% (0.1570.01) in VPA when
compared to the control group (0.2170.01), Po0.01.
2.4. Glutathione content
Other metabolic destiny of glutamate is GSH, synthesized in the
cytosol via two ATP-requiring enzymatic steps: the formationof g-glutamylcysteine from L-glutamate and L-cysteine, and the
formation of GSH from g-glutamylcysteine and glycine.
As showed in Table 1, although there was a higher GSH content
in VPA rats at P15, this difference was not statistically signifi-
cant. On the other hand, VPA group showed a significantly
increase (27%) in GSH content at P120. The absolute values
(nmol/mg protein) changed from 1.070.40 (control) to 1.870.5
(VPA) at P15 and from 51.7774.06 (control) to 65.6973.59 (VPA),
at P120 (Po0.05).3. Discussion
The involvement of glial alterations in a large variety of CNS
diseases is now easy to conceive once it is well established
that the active brain displays a network of integrated and
interactive neurons and glial cells. Yet, only recently this
concept has been applied in understanding the pathogenesis
and pathophysiology of autism, including studies on micro-
glia (Morgan et al., 2010), oligodendrocytes (Carmody and
Lewis, 2010) and astrocytes (Fatemi et al., 2008).
Astrocytes may represent an important and potential source
of investigation to evaluate mechanisms that might be related
to brain dysfunctions in ASD. Given their critical role in
maintenance of neuronal microenvironment and modulation
Fig. 3 – The effect of prenatal exposure to VPA on hippocampal
GLT1 immunocontent. Homogenized tissue samples were
incubated as described in experimental procedure section.
Each sample was measured in duplicate and data analysis
was performed by Student’s t test. Data represent the
mean7SE values. A) P15 (n¼4) and B) P120 (n¼4) days old
rats. Statistically significant difference from control values
is indicated by Po0.05 and #Po0.01.
Fig. 4 – The effect of prenatal exposure to VPA on hippocampal
GS activity. Homogenized tissue samples were incubated as
described in experimental procedure section. Each sample
was measured in triplicate and data analysis was
performed by Student’s t test. Data represent the mean7SE
values. (A) P15 (n¼8 for control group and n¼10 for VPA
group) and (B) P120 (n¼4) days old rats. Statistically
significant difference from control values is indicated
by Po0.05 and #Po0.01.
Table 1 – The effect of prenatal exposure to VPA on
hippocampal GSH.
P15 P120
Control 1.070.40 51.7774.06
VPA 1.870.50 65.6973.59
Homogenized tissue samples were incubated as described in
experimental procedure section. Each sample was measured in
triplicate and data analysis was performed by Student’s t test. Data
are expressed as mean7SE at P15 (n¼4) and P120 (n¼7) days old
rats. Significant difference from control values is indicated by
n Po0.05.
b r a i n r e s e a r c h 1 4 9 5 ( 2 0 1 3 ) 5 2 – 6 0 55of excitatory synapses, individual astrocytes occupy distinct,
non-overlapping domains and extend fine membranous pro-
cesses that may ensheat about 140,000 synapses (Benarroch,
2009). It has also been estimated that more than 99% of
cerebrovascular surface is ensheathed by astrocytic processes
(Nimmerjahn, 2009). Hence, the comprehension of astrocyte
functions and the involvement of these cells in ASD offer the
potential for developing novel strategies to improve autism
symptoms. In addition, as most of basic research on autism
focuses on adolescent or adult rats, there is a clearly lack for
studies in early postnatal stages of development. In the present
work, samples from young rats (P15) were included for the first
time in the evaluation demonstrating, in addition of prenatal
VPA effects, interesting differences between young and adult
ages. Our experiments were done using the hippocampus as the
target structure once it might be responsible for the cognitive
deficits and impairments in affective behavior and emotional
regulation in patients with autism (Bauman and Kemper, 2005;
Dager et al., 2007; Groen et al., 2010; Schumann et al., 2004).
In this context, the present data contribute to a better
understanding of neural alterations, closer to the time point
of VPA induction, in which autism-like features are triggered
in this experimental model. As it is difficult to determine if
the neural alterations observed in older VPA treated rats are
cause or consequence of the disorder, the understandingof early postnatal neural changes are of great relevance in
ASD studies. Accordingly, from a translational perspective
(Clancy et al., 2001), this kind of study may provide new clues
concerning the factors involved in triggering ASD and may
contribute to the development of new therapeutic strategies
or diagnostic criteria.
In the present data we are showing, for the first time, an
important age dependent difference in hippocampal gluta-
mate uptake from rats after prenatal exposure to VPA, with a
significant increase in glutamate uptake at P120. Glutamate
b r a i n r e s e a r c h 1 4 9 5 ( 2 0 1 3 ) 5 2 – 6 056seems to play an important role on autism development
(Choudhury et al., 2011) and, once its homeostasis is strongly
dependent upon glial status (McKenna, 2007; Wang and
Bordey, 2008), our findings could highlight a biologically
significant pathway possibly involved on the pathophysiology
of autism.
Our data show an age-dependent reduction in glutamate
uptake, as evidenced by results obtained with P15 and P120
control rats, which is in accordance with the literature
(Thomazi et al., 2004). We found that this effect was still
observed after prenatal exposure to VPA. Once this effect may
be explained by higher glutamate transporter expression
(GLAST and GLT-1), as described in the literature (Thomazi
et al., 2004), we decided to investigate the protein expression
of the glial glutamate transporters. Despite the changes in
glutamate uptake observed in VPA group at P15 and P120, the
protein expression of GLAST was unchanged both in young
and adult rats. Interestingly, prenatal exposure to VPA
induced an age-dependent pattern of GLT1 expression, with
40% reduction in P15 and 92% increase in P120. Develop-
mental studies showed that GLT1 display a significant transi-
tion period between postnatal 10 and 20 days with huge
variations in its expression, while hippocampal GLAST is
more stable around the same period (Furuta et al., 1997;
Kugler and Schleyer, 2004). Therefore, the instability of GLT1
expression may explain the different profile in glutamate
uptake observed in young animals. We also must have in
mind that, although GLT1 is decreased in P15, we do not have
information about its functionality and since we are dealing
with a brain maturation period, the effectiveness of gluta-
mate uptake may not be a direct reflect of transporters
amount. In addition, it is known that neuronal activity exerts
influence over GLT1 dynamics (Benediktsson et al., 2012).
Since P15 brain is still in development, changes in neuronal
number and function may also contribute to this unstable
context of transporter amount and uptake efficacy.
To clarify the fate of astrocytic glutamate, which is
increased on hippocampus from adult VPA rats, we investi-
gated GS activity since it is expected that glutamate could be
naturally converted in glutamine by astrocytes. However, GS
activity was increased only at P15 in spite of the unchanged
glutamate uptake observed at this age. In addition, a
decreased activity of GS was observed in hippocampus from
P120 rats, contrasting with the increased glutamate uptake
found in this age, indicating that the additional amount of
astrocytic glutamate has probably been deviated to other
pathway. A plausible possibility is that glutamate might have
been directed to energetic metabolism to compensate a
disturbance of mitochondrial energy production, considering
that in humans there is evidence of mitochondrial alterations
in autism (Guevara-Campos et al., 2011). In addition, there is
evidence that excessive Ca2þ levels are responsible for boost-
ing aspartate–glutamate carrier (AGC) activity, mitochondrial
metabolism and, in a more variable degree, oxidative stress in
brains from patients with ASD (Palmieri et al., 2010; Palmieri
and Persico, 2010). Besides, considering that GS activity has
been associated with astrocyte maturation during nervous
system development Patel et al. (1983)), the decreased GS
activity observed in adult rats may therefore reflect impair-
ment in astrocytic maturation in prenatally exposed VPA rats.The activity of GS displayed an age-dependent decrease as
shown by control group results. It is well known that the aged
brain display neural environment alterations which makes it
more susceptible to neurodegenerative diseases. Some of these
alterations include a pro-inflammatory profile characterized by
higher levels of reactive species and pro-inflammatory cyto-
kines (Bodles and Barger, 2004; Campuzano et al., 2009). In this
context some authors have shown that oxygen reactive species
and cytokines such as TNF-a are known to negatively influence
GS activity (Santin et al., 2011; Zou et al., 2010), which might
therefore, explain our results. Besides, despite the increased
glutamate uptake observed in P120 VPA rats, this group showed
also increased GSH levels. This is consistent with an endogen-
ous protection against a pro-oxidative environment, consuming
glutamate, decreasing it as a substrate for GS function, which in
turn may decrease its activity.
Nevertheless, glutamate also serves as a substrate per se for
GSH synthesis. In addition, it acts in the glutamate–cystine
antiporter, promoting the increase of intracellular cysteine,
another substrate for GSH synthesis (Dringen et al., 1999).
Interestingly, we observed a significantly increase in the con-
tent of reduced GSH in VPA group at P120, reinforcing the
antioxidant role of astroglial cells mediated by prenatal expo-
sure to VPA. In fact, the pathology of autism has been correlated
with alterations in oxidative stress parameters (James et al.,
2006), including GSH metabolism, mitochondrial dysfunctions
and elevation of oxidative stress markers. Besides, increased
levels of reactive species in the hippocampus from patients
with autism have been documented (Palmieri et al., 2010;
Palmieri and Persico, 2010) and this might be a possible
explanation for the persistently increase of GSH levels demon-
strated in the present work. Although both GSH and GSSG occur
in tissues, more than 99.5% of the total tissue glutathione (i.e.,
GSHþGSSG, in GSH equivalents) are in the form of reduced GSH
(Anderson et al., 1985).Thus, an increased hippocampal content
of reduced GSH could at least partially explain one of the fate of
glutamate, towards GSH biosynthesis.
Furthermore, the increased AGC activity in autistic brain could
imply in a higher transport of glutamate into the mitochondrial
matrix (Napolioni et al., 2011; Palmieri et al., 2010; Palmieri and
Persico, 2010.). As a consequence, an increased feeding of the
TCA cycle with this amino acid could amplify the loading of
energetic metabolism pathways (Chauhan et al., 2011; Weissman
et al., 2008), with a respiratory chain overload, triggering the
production of reactive species and thereby justifying the require-
ment of high GSH levels. In this way, the GSH role in autism core
could be more important than actually believed.
The present data are summarized in Fig. 5, which also
demonstrates a neuroglial hypothesis to the glutamate meta-
bolism alterations in ASD. Physiologically, once into the astro-
cyte, glutamate can be directed to four major pathways
(McKenna, 2007): (1) Protein synthesis and degradation, which
flows as an essential and continuous cellular process; (2)
glutamine synthesis through GS, which converts glutamate
plus ammonia and ATP into glutamine and ADP; (3) GSH
synthesis, the most abundant non-protein thiol and (4) ener-
getic metabolism, since glutamatergic synapse represents a
major energetic cost (Alle et al., 2009) and involves metabolic
coupling between neurons and perisynaptic astroglial processes
(Magistretti, 2009). Interestingly, The VPA group showed and
Fig. 5 – Glutamate metabolism at the tripartite synapse.
Hypothesis for the influence of animal model of autism in
rats prenatally exposed to VPA on glutamate metabolism at
P15 and P120 days-old. The scheme illustrates: (1) Glu
release at the synaptic cleft; (2) Glu uptake by astrocytes
which is mediated two glutamate transporters: GLAST,
which had no alterations in its protein expression and
GLT1, which was decreased in P15 and increased in P120;
(3) Glu conversion into glutamine (Gln) by the enzyme Gln
synthetase (GS) and (4) the uptake of Gln by neurons
followed by Glu resynthesis via glutaminase. Rats
prenatally exposed to VPA at P15 increased GS activity,
while at P120 increased glutamate uptake and decreased
GS activity. Additionally, VPA group increased the synthesis
of (5) glutathione (GSH) at P120, another important fate
of glutamate in astrocytes. * ¼ increase, + ¼decrease.
b r a i n r e s e a r c h 1 4 9 5 ( 2 0 1 3 ) 5 2 – 6 0 57increased GS activity at P15 accompanied by a decrease in GLT1
amounts, which is a pattern observed in acute brain injuries
(Lehmann et al., 2009; Sheldon and Robinson, 2007). On the
other hand, GS activity was higher in P120 VPA rats, which also
showed an increase inGLT1 content and in glutamate uptake,
combined with increased GSH synthesis. These findings have
stimulated the view that the active brain should be regarded as
a circuit of integrated and interactive neurons and glial cells.
Consequently, astrocyte cells could also have important roles in
ASD and an improved understanding of astrocyte biology and
heterogeneity and the involvement of these cells in autism
offers the potential for developing novel strategies to treat
neurological disorders.
In summary, the present data highlights that the astrocyte
clearance of glutamate from the synaptic cleft and its metabolic
destiny are important aspects to be considered from both
pathophysiologic and pharmacological approaches in ASD4. Experimental procedure
4.1. Subjects
Female Wistar rats were obtained from the local breeding
colony (ICBS-Federal University of Rio Grande do Sul), with
12:12 light cycle (lights on at 7:00 and lights off at 19:00),controlled temperature (2271 1C), water and food ad libitum.
They were handled in accordance to the governmental and
Brazilian Experimental Biology Societies Federation guide-
lines. The estrous cycle was monitored and females were
mated overnight. The first day of gestation was considered
when spermatozoa were found in the vaginal smear. Valproic
acid (Acros Organics, New Jersey, USA) was purchased as the
sodium salt and dissolved in 0.9% saline for a concentration
of 250 mg/mL. Females received a single intraperitoneal
injection of valproic acid (600 mg/kg, 250 mg/mL diluted in
NaCl 0.9%) in the 12.5th day of pregnancy and control females
received physiological saline at the same time as previously
described (Bambini-Junior et al., 2011; Schneider and
Przewlocki, 2005). Females were housed individually and
were allowed to raise their own litters. The offspring rats
were housed separately by sex. Male pups from three differ-
ent litters were killed by decapitation at postnatal day 15 (P15
group) or 120 (P120 group). The brains were removed and
hippocampal samples were kept in 801C until the assays
were performed, except those used for glutamate uptake
evaluation, which need fresh tissue to be realized. The
number of animals used in each technique varied and is
described in the following sections.
4.2. Glutamate uptake assay
Glutamate uptake was performed as previously described
(Gottfried et al., 2002). Briefly, hippocampal sections obtained
from P15 (n¼5) and P120 (n¼4) rats were incubated at 37 1C in
a Hank’s Balanced Salt Solution (HBSS) containing (in mM):
137 NaCl; 5.36 KCl, 1.26 CaCl2, 0.41 MgSO4, 0.49 MgCl2, 0.63
Na2HPO4  7H2O, 0.44 KH2PO4, 4.17 NaHCO3 and 5.6 glucose,
adjusted to pH 7.4. The assay was started by addition of
0.1 mM L-glutamate and 0.33 mCi/ml L-[2,3-3H] glutamate.
Incubation was stopped after 10 min by removal of the
medium and rinsing the cells twice with ice-cold HBSS. The
cells were then lysed in a solution containing 0.5 M NaOH.
Radioactivity was measured in a scintillation counter. Final
glutamate uptake (expressed as nmol/mg prot/min) was
obtained by discounting non-specific uptake in assays carried
out in sodium-free medium, prepared by replacing NaCl with
choline chloride in the HBSS.
4.3. Protein expression of GLAST and GLT1
Hippocampal tissue homogenates obtained from P15 and
P120 rats (n¼4 for both VPA and control groups) were used.
Equal amounts (20 mg) of proteins from each sample were
boiled in sample buffer (0.0625 M Tris-HCl, pH 6.8, 2% (w/v)
SDS, 5% (w/v) b-mercaptoethanol, 10% (v/v) glycerol, 0.002%
(w/v) bromophenol blue) and electrophoresed in 10% (w/v)
SDS-polyacrylamide gel. The separated proteins were blotted
onto a nitrocellulose membrane. Equal loading of each
sample was confirmed with Ponceau S staining (Sigma) and
using an anti-b-tubulin (MAB1637, Millipore). Membranes
were blocked (overnight, 4 1C) with 5% albumin in T-TBS
(10 mM Tris, 150 mM NaCl, pH 7.5) Anti-EAAT1 (AB416,
Abcam) and Anti-EAAT2 (AB41621, Abcam) were used at a
dilution of 1:1000. After incubating with the primary antibody
overnight at 4 1C, membranes were washed and incubated
b r a i n r e s e a r c h 1 4 9 5 ( 2 0 1 3 ) 5 2 – 6 058with peroxidase-conjugated anti-mouse immunoglobulin
(NA931V IgG, GE) at a dilution of 1:2000 at 4 1C overnight.
The chemiluminescence signal was detected using an ECL kit
from Amersham. Images were analyzed using Scion Image
for Windows.4.4. Glutamine synthetase activity
The enzymatic assay was performed as previously described
(dos Santos et al., 2006). Briefly, tissue homogenate (0.1 mL)
from P15 (n¼8 for control group and n¼10 for VPA group) and
P120 (n¼4 in both groups) rats were added to 0.1 mL of the
reaction mixture containing (in mM): 10 MgCl2; 50 L-gluta-
mate; 100 imidazole–HCl buffer (pH 7.4); 10 2-mercaptoetha-
nol; 50 hydroxylamine–HCl; 10 ATP and incubated for 30 min
at 37 1C. The reaction was stopped by the addition of 0.4 ml of
a solution containing (in mM): 370 ferric chloride; 670 HCl; 200
trichloroacetic acid. After centrifugation, the supernatant’s
absorbance was measured at 530 nm and compared to the
absorbance generated by standard quantities of g-glutamyl-
hydroxamate, treated with ferric chloride reagent.4.5. Glutathione content
The GSH content was determined, as described before
(Browne and Armstrong, 1998). Briefly, hippocampal samples
obtained from P15 (n¼4) and P120 (n¼7) rats homogenized in
sodium phosphate buffer (0.1 M, pH 8.0) containing 5 mM
EDTA and protein were precipitated with 1.7% meta-
phosphoric acid. The supernatant was assayed with o-phthal-
dialdehyde (1 mg/mL of methanol) at room temperature for
15 min. Fluorescence was measured using excitation and
emission wavelengths of 350 and 420 nm, respectively.
A calibration curve (0–500 mM) was performed with standard
GSH solution. Results are expressed as % of control and the
number of animals used was four and seven rats per group at
P15 and P120, respectively.4.6. Protein determination
Protein content was determined as previously described
(Lowry et al., 1951), using bovine serum albumin as standard.4.7. Statistical analysis
Data are presented as mean7SE and were analyzed statisti-
cally by Student’s t test and Po0.05 was considered as
statistically significant. All analyses were carried out using
the Statistical Package for Social Sciences (SPSS) software.Acknowledgments
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